Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1

• Published in: Oncotarget Vol. 7; no. 28; pp. 44096 - 44112
• Main Authors: Coyle, Krysta M, Murphy, J Patrick, Vidovic, Dejan, Vaghar-Kashani, Ahmad, Dean, Cheryl A, Sultan, Mohammad, Clements, Derek, Wallace, Melissa, Thomas, Margaret L, Hundert, Amos, Giacomantonio, Carman A, Helyer, Lucy, Gujar, Shashi A, Lee, Patrick W K, Weaver, Ian C G, Marcato, Paola
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 12.07.2016
• Subjects: Aldehyde Oxidoreductases - genetics; Aldehyde Oxidoreductases - metabolism; ALDH1A3; Animals; breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cell Line, Tumor; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins - genetics; Membrane Proteins - metabolism; Mice, Inbred NOD; Mice, SCID; Middle Aged; Prognosis; Protein Interaction Maps - genetics; RARRES1; Research Paper; retinoic acid; RNA Interference; Transplantation, Heterologous; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - pathology; Tumor Burden - genetics; DNA methylation; ALDH1A3; breast cancer; retinoic acid; RARRES1

Breast cancer subtyping, based on the expression of hormone receptors and other genes, can determine patient prognosis and potential options for targeted therapy. Among breast cancer subtypes, tumors of basal-like and claudin-low subtypes are typically associated with worse patient outcomes, are pri...